• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Geburtshilfe und Frauenheilkunde >Methylenetetrahydrofolate Reductase Polymorphisms and Pregnancy Outcome
【24h】

Methylenetetrahydrofolate Reductase Polymorphisms and Pregnancy Outcome

机译：亚甲基四氢呋喃还原酶多态性和妊娠结局

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction Aim of the study was to evaluate the effect of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on pregnancy outcome. Materials and Methods A total of 617 pregnancies of women who were investigated for MTHFR C677T and A1298C polymorphisms prior to pregnancy were included in the study. Cases were classified into “homozygous polymorphisms” (Group I), “heterozygous polymorphisms” (Group II), and patients without polymorphisms who functioned as controls (Group III). Patients with polymorphisms were assigned to a specific protocol at least 3 months before becoming pregnant. Administration of low molecular weight heparin (LMWH) was started very early during pregnancy. The Beksac Obstetrics Index (BOI) was used to estimate the obstetric risk levels for the different groups. Results We found that the early pregnancy loss (EPL) rate increased as MTHFR polymorphism complexity increased and that the early EPL rate was significantly higher in patients with MTHFR C677T polymorphism compared to patients with MTHFR A1298C polymorphism (p = 0.039). There were significant differences between the previous pregnancies of the patients in the 3 study groups in terms of perinatal complications and EPLs (p = 0.003 and p = 0.019). The BOI decreased as the severity of polymorphisms increased. An association between MTHFR polymorphisms and congenital malformations and chromosomal abnormalities was observed. We could not demonstrate any statistically significant difference between study groups when the 3 groups were compared with regard to the pregnancy outcomes under specific management protocols. Conclusion MTHFR polymorphisms are potential risk factors for adverse pregnancy outcomes.
机译：介绍该研究的目的是评估亚甲基丁二醇还原酶（MTHFR）多态性对妊娠结局的影响。研究中，材料和方法共有617名对MTHFR C677T和妊娠期之前的A1298C多态性进行调查的妇女孕妇。病例被分类为“纯合多态性”（Ⅰ组），“杂合多态性”（II族），以及没有多态性的患者，患者作为对照（III组）。在怀孕前至少3个月将多态性患者分配给特定的方案。妊娠期间早期开始肝素（LMWH）的低分子量肝素（LMWH）。 BEKSAC产科指数（BOI）用于估计不同群体的产科风险水平。结果发现，随着MTHFR多态性复杂性的增加，妊娠早期损失（EPL）速率增加，与MTHFR A1298C多态性患者相比，MTHFR C677T多态性患者的早期EPL速率显着高（P = 0.039）。在围产期并发症和EPLS方面，3项研究组之前对患者的先前怀孕之间存在显着差异（P = 0.003和P = 0.019）。随着多态性的严重程度增加，Boi减少。观察到MTHFR多态性和先天性畸形和染色体异常之间的关联。当在特定管理方案下的妊娠结算方面，我们无法展示研究组之间的任何统计学意义。结论MTHFR多态性是不良妊娠结果的潜在危险因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号